rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Marker Therapeutics, Inc.

MRKR · Nasdaq

Health CareBiotechnologyNot moving yet

MRKR stood above a rising 150-day average in 19 of the last 52 weekly readings, and has been out of that trend for the last 15 weeks. It is 12.5% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−14 points in four weeks); Health Care: 28% (−9 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 15
Industry in uptrend
18% -14 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
34 (+0)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 19 of 52 weeks.

21 Apr – 20 Oct
18%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$1.7MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders34+0 on the quarter
New · exited4 · 4
Reported value$5.8M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
NEA Management Company, LLCunchanged · filed 14 Aug 20261,625,678$2.4M00.0%
Blue Owl Capital Holdings LPunchanged · filed 11 Aug 2026554,250$815K00.0%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026426,169$626K+36,850+9.5%
Aisling Capital Management LPunchanged · filed 13 Aug 2026325,370$478K00.0%
RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 2026249,423$367K+74,129+42.3%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026139,816$206K-21,094−13.1%
OSAIC HOLDINGS, INC.added · filed 14 Aug 2026112,649$166K+19,528+21.0%
VANGUARD FIDUCIARY TRUST COunchanged · filed 13 Aug 202687,269$128K00.0%
LPL Financial LLCadded · filed 7 Aug 202683,147$122K+100+0.1%
Concurrent Investment Advisors, LLCnew · filed 27 Jul 202667,963$100K+67,963
31 Mar 2023 – 30 Jun 2026
222935Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Katharine Knobil Company insiderDirector · last 17 Nov 20250 · 0
Norman David Eansor Company insiderDirector · last 17 Nov 20251 · 0
Steve Elms Company insiderDirector · last 17 Nov 20252 · 0
Juan Vera Company insiderChief Executive Officer · last 31 Oct 20251 · 0
Kathryn Penkus Corzo Company insiderDirector · last 31 Oct 20250 · 0
Nea Partners 16, L.p. Company insider10% owner · last 23 Dec 20242 · 0
John Robert Wilson Company insiderDirector · last 6 Jun 20231 · 0
Anna Szymanska Company insiderVice President, Quality · last 27 Feb 20230 · 0
Michael Loiacono Company insiderChief Accounting Officer · last 27 Feb 20230 · 0
Mythili Koneru Company insiderChief Medical Officer · last 27 Feb 20230 · 0
Nadia Agopyan Company insiderSVP, Regulatory Affairs · last 27 Feb 20230 · 0
Tsvetelina P. Hoang Company insiderVP, Research and Development · last 27 Feb 20230 · 0

Same industry

MRNA ModernaLeading+167%
ENTX Entera BioLeading+52%
XNCR XencorLeading+41%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Operating profit marginFY 2025 · to 31 Dec 2025-363%
Return on capital employedFY 2025 · to 31 Dec 2025-76.7%
Research spendFY 2025 · to 31 Dec 2025333%
Share count trendFY 2025 · to 16 Mar 2026-0.2%
Cash and equivalentsFY 2025 · to 31 Dec 2025$16.1M

Analyst forecasts

No analyst forecasts yet.